HOLLY SPRINGS, N.C.
Novartis opened its influenza vaccine manufacturing facility in Holly Springs, N.C., in November of 2009. The $1 billion project was developed in partnership with the U.S. Department of Health and Human Services. The facility is designed to supply 150 million doses of vaccine within six months of the declaration of a pandemic. The building supports a cell culture-based manufacturing process and is expected to reach full-scale commercial production in 2013.
